Back to School: How biopharma can reboot drug development. Access exclusive analysis here
FDA's Cardiovascular & Renal Drugs Advisory Committee voted 7-0 on Wednesday to recommend against FDA approval of Pulzium tedisimal
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury